NRX Pharmaceuticals Inc. Reports Debt‑Free Balance Sheet via Equity Conversion
Date: 18 December 2025Ticker: NRXP (Nasdaq)
NRX Pharmaceuticals Inc., a clinical‑stage biopharmaceutical company focused on investigational medicines for Covid‑19, respiratory conditions, suicidal depression, and PTSD, announced that it has eliminated all balance‑sheet debt. The company achieved this milestone by converting outstanding debt into equity, thereby repaying a $5.4 million obligation to Anson Funds, LLC.
Transaction Details
| Item | Amount | Notes |
|---|---|---|
| Outstanding debt repaid | $5.4 million | Converted from debt to common stock; no warrants or other repricing mechanisms were involved. |
| Original loan amount | $16.2 million | Provided by Anson Funds to finance prior loans and operating expenses. |
| Equity conversion | Debt holder received shares of NRX common stock in exchange for the repayment. | |
| Balance‑sheet status | Debt‑free | Company expects to finish 2025 without any balance‑sheet debt. |
Strategic Implications
- Capital structure: A debt‑free balance sheet positions NRX for accelerated growth, with improved credit metrics and lower financial risk.
- Future funding: The company anticipates that the strengthened capital structure will support anticipated drug approvals and clinic expansions planned for 2026.
- Investor confidence: The repayment demonstrates effective use of capital and reinforces the partnership with Anson Funds during a challenging period for biotechnology equities.
Market Context
- Share price (17 Dec 2025 close): $2.18.
- 52‑week range: $1.40 – $6.01.
- Market cap: $64.06 million USD.
- P/E ratio: –1.04 (negative due to ongoing research and development expenses).
The announcement was made through a GlobeNewswire press release and reported by multiple financial news outlets, including feeds.feedburner.com, www.wallstreet-online.de , and www.globenewswire.com .
Conclusion
NRX Pharmaceuticals has successfully removed all balance‑sheet debt by converting it into equity, thereby strengthening its financial position as it moves toward key regulatory milestones and expansion plans in the coming year.
